dr. tyna moore glp-1 I was recently joined by and Calley Means on The Doctor's Farmacy for a controversial discussion of agonists like Ozempic, weighing the pros and cons of these peptides I was joined by Dr.

Back Brandt, SJ, Mller, TD, DiMarchi, RD, et al (12 Sept 2018) 'Peptide-based multi-agonists: a new paradigm in metabolic pharmacology', Journal of Internal Medicine

(2022) 12(9):e060668

Therefore, antidiabetic medication decreases blood sugar levels, reduces body weight through a reduction in appetite [94], and lowers glycated hemoglobin (HbA1c), all while having a low risk of causing hypoglycemia [104]

A group of researchers, including oncologists and data scientists, from the University of Florida and Indiana University hypothesized that GLP-1s hold promise in oncology due to their ability to lower glucose, adiposity, insulin resistance, and systemic inflammation factors associated with cancer progression, according to a July 2025 paper published in JAMA